• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

影响肾病综合征糖皮质激素治疗终止后心血管风险的因素。

Factors influencing cardiovascular risk following termination of glucocorticoid therapy for nephrotic syndrome.

机构信息

Department of Paediatrics, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.

出版信息

Clin Exp Nephrol. 2010 Oct;14(5):457-62. doi: 10.1007/s10157-010-0317-9. Epub 2010 Jul 17.

DOI:10.1007/s10157-010-0317-9
PMID:20640586
Abstract

BACKGROUND

This study attempted to identify the cardiovascular risk factors associated with retention of excess weight following termination of glucocorticoid therapy in children with nephrotic syndrome.

METHODS

We performed a retrospective study of 30 Japanese children (18 males, 12 females, aged 1-14 years) who had been treated with glucocorticoids for steroid-sensitive nephrotic syndrome and 32 control children (17 males, 15 females, aged 1-15 years). The subjects receiving glucocorticoid therapy were divided into a retention group (n = 14) or a reduction group (n = 16) on the basis of the presence or absence of a maintained body mass index (BMI) following glucocorticoid termination. BMI z-scores, age, gender, blood pressure, serum total cholesterol levels (T-cho), and the dose and duration of glucocorticoid exposure were evaluated in each group during the study period.

RESULTS

The retention group had a significantly (P < 0.05) increased dose and duration of glucocorticoid exposure, and of T-cho at the time of last visit compared with the control or reduction group. Moreover, logistic regression analysis showed that the adjusted odds ratio for T-cho at the time of last visit in the retention group was significantly higher (P < 0.05) relative to the reduction group.

CONCLUSION

Retention of excess weight during the period of remission from nephrotic syndrome following cessation of glucocorticoid therapy was related to the dose and duration of glucocorticoid exposure and was associated with hyperlipidemia, which might enhance cardiovascular risk.

摘要

背景

本研究旨在确定与糖皮质激素治疗肾病综合征患儿停药后超重持续相关的心血管危险因素。

方法

我们对 30 名接受糖皮质激素治疗的日本儿童(男 18 例,女 12 例,年龄 1-14 岁)和 32 名对照儿童(男 17 例,女 15 例,年龄 1-15 岁)进行了回顾性研究。根据糖皮质激素停药后体重指数(BMI)是否保持,将接受糖皮质激素治疗的患儿分为保留组(n=14)或减少组(n=16)。在研究期间,评估了每个组的 BMI z 评分、年龄、性别、血压、血清总胆固醇(T-cho)水平以及糖皮质激素暴露的剂量和持续时间。

结果

保留组糖皮质激素暴露的剂量和持续时间以及最后一次就诊时的 T-cho 明显高于(P<0.05)对照组或减少组。此外,逻辑回归分析显示,保留组最后一次就诊时 T-cho 的调整比值比明显高于(P<0.05)减少组。

结论

糖皮质激素治疗肾病综合征缓解后停药期间超重的保留与糖皮质激素暴露的剂量和持续时间有关,并与高脂血症有关,这可能增加心血管风险。

相似文献

1
Factors influencing cardiovascular risk following termination of glucocorticoid therapy for nephrotic syndrome.影响肾病综合征糖皮质激素治疗终止后心血管风险的因素。
Clin Exp Nephrol. 2010 Oct;14(5):457-62. doi: 10.1007/s10157-010-0317-9. Epub 2010 Jul 17.
2
Body weight changes in children with idiopathic nephrotic syndrome.特发性肾病综合征患儿的体重变化
Dev Period Med. 2016 Jan-Mar;20(1):16-22.
3
Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome.激素敏感型肾病综合征患儿糖皮质激素诱导肥胖的危险因素
Pediatr Nephrol. 2006 Jul;21(7):973-80. doi: 10.1007/s00467-006-0100-z. Epub 2006 May 30.
4
Interactions between growth and body composition in children treated with high-dose chronic glucocorticoids.接受大剂量慢性糖皮质激素治疗的儿童生长与身体成分之间的相互作用。
Am J Clin Nutr. 2004 Nov;80(5):1334-41. doi: 10.1093/ajcn/80.5.1334.
5
Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome.儿童糖皮质激素敏感型肾病综合征中长效、大剂量糖皮质激素与骨矿物质含量的关系
N Engl J Med. 2004 Aug 26;351(9):868-75. doi: 10.1056/NEJMoa040367.
6
Changes in body mass index in long-term survivors of childhood acute lymphoblastic leukemia treated without cranial radiation and with reduced glucocorticoid therapy.未行颅脑放疗且糖皮质激素治疗剂量减少的儿童急性淋巴细胞白血病长期生存者的体重指数变化。
Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26344. Epub 2016 Nov 10.
7
Expression of P-glycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids.糖皮质激素治疗的肾病综合征患儿淋巴细胞中P-糖蛋白的表达
Eur J Pediatr. 2006 Dec;165(12):839-44. doi: 10.1007/s00431-006-0177-1.
8
Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.十六周与标准八周泼尼松治疗儿童肾病综合征的随机对照试验:PREDNOS RCT。
Health Technol Assess. 2019 May;23(26):1-108. doi: 10.3310/hta23260.
9
Genotypes of the renin-angiotensin system and glucocorticoid complications.肾素-血管紧张素系统的基因型与糖皮质激素并发症
Pediatr Int. 2015;57(1):72-8. doi: 10.1111/ped.12434. Epub 2015 Jan 16.
10
Corticosteroid therapy for nephrotic syndrome in children.儿童肾病综合征的皮质类固醇治疗
Cochrane Database Syst Rev. 2003(1):CD001533. doi: 10.1002/14651858.CD001533.

引用本文的文献

1
Evaluation of carotid intima media thickness in children with idiopathic nephrotic syndrome.评价特发性肾病综合征患儿的颈动脉内膜中层厚度。
Ital J Pediatr. 2022 Dec 9;48(1):195. doi: 10.1186/s13052-022-01383-7.
2
Assessment of Carotid Intima Media Thickness and Left Ventricular Mass Index in Children with Idiopathic Nephrotic Syndrome.特发性肾病综合征患儿的颈动脉内膜中层厚度及左心室质量指数评估
Vasc Health Risk Manag. 2021 Jun 10;17:349-356. doi: 10.2147/VHRM.S295868. eCollection 2021.
3
Augmentation index, a predictor of cardiovascular events, is increased in children and adolescents with primary nephrotic syndrome.

本文引用的文献

1
Management of childhood onset nephrotic syndrome.儿童期肾病综合征的管理
Pediatrics. 2009 Aug;124(2):747-57. doi: 10.1542/peds.2008-1559. Epub 2009 Jul 27.
2
Gender in childhood obesity: family environment, hormones, and genes.儿童肥胖中的性别因素:家庭环境、激素和基因。
Gend Med. 2009;6 Suppl 1:76-85. doi: 10.1016/j.genm.2008.12.001.
3
Atherosclerosis risk factors in young patients formerly treated for idiopathic nephrotic syndrome.曾接受特发性肾病综合征治疗的年轻患者的动脉粥样硬化危险因素。
增强指数是心血管事件的预测因子,在原发性肾病综合征的儿童和青少年中升高。
Pediatr Nephrol. 2020 May;35(5):815-827. doi: 10.1007/s00467-019-04434-0. Epub 2019 Dec 16.
4
Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil prednisone: protocol for a randomised, controlled, multicentre trial (INTENT study).霉酚酸酯联合泼尼松治疗儿童激素敏感型特发性肾病综合征:一项随机对照多中心试验方案(INTENT研究)
BMJ Open. 2018 Oct 10;8(10):e024882. doi: 10.1136/bmjopen-2018-024882.
5
Subclinical cardiovascular disease and its association with risk factors in children with steroid-resistant nephrotic syndrome.隐匿性心血管疾病及其与激素抵抗型肾病综合征患儿危险因素的关联。
Pediatr Nephrol. 2014 Jan;29(1):95-102. doi: 10.1007/s00467-013-2608-3. Epub 2013 Sep 15.
Pediatr Nephrol. 2009 Mar;24(3):549-54. doi: 10.1007/s00467-008-1029-1. Epub 2008 Oct 30.
4
Body mass index reference values (mean and SD) for Japanese children.日本儿童的身体质量指数参考值(均值和标准差)。
Acta Paediatr. 2007 Nov;96(11):1674-6. doi: 10.1111/j.1651-2227.2007.00490.x.
5
Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome.激素敏感型肾病综合征患儿糖皮质激素诱导肥胖的危险因素
Pediatr Nephrol. 2006 Jul;21(7):973-80. doi: 10.1007/s00467-006-0100-z. Epub 2006 May 30.
6
Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome.激素敏感型肾病综合征患儿成年:长期预后
J Pediatr. 2005 Aug;147(2):202-7. doi: 10.1016/j.jpeds.2005.03.050.
7
Diagnosis and complications of Cushing's syndrome: a consensus statement.库欣综合征的诊断与并发症:一项共识声明。
J Clin Endocrinol Metab. 2003 Dec;88(12):5593-602. doi: 10.1210/jc.2003-030871.
8
Tissue glucocorticoid resistance/hypersensitivity syndromes.组织糖皮质激素抵抗/超敏综合征
J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):457-67. doi: 10.1016/s0960-0760(03)00218-8.
9
Overweight children and adolescents: description, epidemiology, and demographics.超重儿童和青少年:描述、流行病学及人口统计学特征
Pediatrics. 1998 Mar;101(3 Pt 2):497-504.
10
Prescription medications: a modifiable contributor to obesity.处方药:肥胖的一个可改变的促成因素。
South Med J. 1999 Sep;92(9):898-904. doi: 10.1097/00007611-199909000-00009.